US Stock MarketDetailed Quotes

SNGX Soligenix

  • 6.0700
  • -0.3200-5.01%
Close Jul 19 16:00 ET
  • 5.9246
  • -0.1454-2.40%
Post 19:59 ET
5.99MMarket Cap-621P/E (TTM)

About Soligenix Company

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Company Profile

Company NameSoligenix
CEODr. Christopher J. Schaber,PhD
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address29 Emmons Drive,Suite B-10
ProvinceNew Jersey
CountryUnited States of America
Zip Code08540-5919

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Christopher J. Schaber,PhD
  • Chairman of the Board, Chief Executive Officer and President
  • 700.49K
  • Dr. Richard Straube, M.D.
  • Senior Vice President and Chief Medical Officer
  • 249.94K
  • Dr. Oreola Donini, PhD
  • Chief Scientific Officer and Senior Vice President
  • 387.59K
  • Jonathan L. Guarino, C.P.A.
  • Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Corporate Secretary
  • 354.69K
  • Gregg Anthony Lapointe, C.P.A.,M.B.A.
  • Independent Director
  • 77.50K
  • Dr. Jerome Bernard Zeldis, M.D.,PhD
  • Independent Director
  • 72.50K
  • Diane L. Parks, M.B.A.
  • Independent Director
  • 70.00K
  • Dr. Robert J. Rubin,M.D.
  • Independent Director
  • 80.00K


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price